CoChat

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.

Abstract

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).

Overview

CoChat Summary

## TL;DR

In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.

## Key findings

  • The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
  • Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
  • Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
  • The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).

## Methods

  • Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
  • Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
  • Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.

## Limitations

  • The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
  • The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
  • Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2307563

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Time-to-First-Event Analysis for Primary and Confirmatory Secondary Efficacy End Points.
Figure 1 Time-to-First-Event Analysis for Primary and Confirmatory Secondary Efficacy End Points.From the PDF

Verification

Claims the paper makes

17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations

37 more claims · 6 with their cited sources checked

Create a free account to see all 75 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

71 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 48 references

Cited by

Items 1,401–1,500 of 3,116

Metadata

Authors
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
Affiliations
  • Cleveland Clinic (US)
  • From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
Venue
New England Journal of Medicine
Published
2023-12-14
Volume
389
Issue
24
Pages
2221-2232
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4388592674
Cited by
3,236
References
42
Citations by year
2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
FWCI
658.51
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • Dspace Repository (Marmara Üniversitesi) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Novo Nordisk Pharma
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.